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ANKÝLOZAN SPONDÝLÝTLÝ HASTALARDA ANTÝ-TNF-ALFA TEDAVÝ ÖNCESÝ VE 
SONRASI SAKROÝLÝAK EKLEMLERÝN MANYETÝK REZONANS ÝLE 
GÖRÜNTÜLENMESÝ
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ÖZET
AMAÇ: Çalýþmanýn amacý, dirençli AS'li hastalarda, anti-TNF-alfa ilaçlarýn etkinliðini ve güvenirliðini yanýsýra, 
manyetik rezonans (MR) görüntüleme ile tedavi öncesi ve sonrasý sakroiliak eklem deðiþiklerini tespit etmektir.
GEREÇ ve YÖNTEM: Modifiye New York taný kriterlerine göre AS tanýsý almýþ, 27 hasta çalýþmaya dahil 
edildi. Sakroiilitis bulgularý, anti-TNF-alfa tedavi öncesi ve sonrasý, Gd-MR ile tespit edildi. Sekiz hastaya, 4 
haftada bir Ýnfliximab 4 mg/kg i.v. infüzyon verildi. Diðer 19 hastaya ise Etanercept 2x25 mg/hafta s.c. verildi. 
Deðerlendirilen klinik ve laboratuvar parametreler; BASDAÝ, BASFÝ, aðrý (VAS skoru), Schöber testi, göðüs 
ekspansiyonu, C-reaktif protein (CRP), eritrosit sedimentasyon hýzý (ESH).
BULGULAR: Hastalarýn çoðu, anti-TNF-alfa tedavilerine iyi yanýt verdi. 24. haftanýn sonunda, takip edilen tüm 
parametrelerde iyileþme gözlendi. MR görüntüleme çalýþmalarýnda, anti-TNF-alfa tedavi sonrasý sadece 3 
hastanýn sakroiliak eklem inflamasyonunda gerileme gözlendi. 
SONUÇ: Aktif AS'li hastalarda, 24. hafta sonunda anti-TNF-alfa ilaçlarý güvenilir ve etkin bulundu. BASDAÝ, 
BASFÝ, aðrý skorlarýnda belirgin düþüþ gözlendi. Fakat, sakroiliak eklemin akut inflamatuvar  bulgularýnda, MR 
görüntüleme ile herhangi bir gerileme tespit edilmedi.
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Magnetic Resonance Imaging of the Sacroiliac Joints in Ankylosing Spondilitis Before and After 
Therapy with Anti-Tumor Necrosis Factor Alpha  
SUMMARY
OBJECTIVE: The goal of this study is to assess the changes in the sacroiliac joints (SÝ) by magnetic resonance 
imaging (MRI) in a 24-week follow-up period and to determine the efficacy and safety of anti-TNF-á therapies 
for refractory AS. 
MATERIALS and METHODS: Twenty-seven patients who met the modified New York criteria for AS were 
enrolled in this study. Activity of sacroiliitis was determined by Gd-MRI scan before and after anti-TNF-á 
treatment. Eight patients received infliximab at a dose of 4mg/kg by intravenous infusion over 2 hours at every 4 
week. Other patients (n=19) were treated with 25mg subcutaneous etanercept twice weekly. Total observational 
period was 24 weeks. The clinical and laboratory variables included: Bath AS Disease Activity Index (BASDAI), 
Bath AS Functional Index (BASFI), pain on a visual analog scale, Schober's index, chest expansion, C-reactive 
protein (CRP), erythrocyte sedimentation rate (ESR).
RESULTS: Most patients responded well to treatment of anti-TNF-á antagonists. At 24 weeks, there was an 
improvement in all of the measures followed. Imaging studies showed decreased inflammation of the SI joints 
after 24 weeks of treatment with anti-TNF-á therapies in 3 patients only. 
CONCLUSION: The anti-TNF-á therapy was found to be safe and effective in treating patients with active AS 
during 24-week study period. The BASDAI, BASFI, VAS of pain were decreased significantly, however  we 
could not determine any regression of acute inflammatory changes of the SI joints as depicted by MRI.
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Ankylosing spondylitis (AS), the prototype of (SSZ), which has a proven beneficial effect for 
spondyloarthritis, is a chronic inflammatory peripheral arthritis and enthesitis and nearly 
5,6rheumatic diseases, leading to progressive spinal imperceptible for spondylitis . 
1ankylosis and deformity . Its pathogenesis is Tumor necrosis factor-alpha (TNF-á) has been 
2 determined in sacroiliac joints of patients with AS. incompletely understood . The fýrst symptoms 
TNF-á mRNA and protein have been identified in the normally occur in the second and thýrd decade of life.  
sacroiliac joint (SI) biopsies of patients with active AS most offen starts with inflammation of the 
disease suggesting a role for this cytokine in the target sacroiliac joints (SI) and affect mainly the axial 
73,4 organ inflammation . Over the past few years several skeleton . Until recently, non-steroidal anti-
placebo controlled and open trials have shown a inflammatory drugs(NSAIDs) and physical therapy 
dramatic response in active AS to TNF-á blocking were the only accepted treatment. The only disease 
8-10modifying antirheumatic drug (DMARDs) that has agents . Studies on magnetic resonance imaging 
been demonstrated to be useful for AS is sulfasalasine (MRI) of SI joints in AS indicate that MRI enables 
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11early diagnosis of sacroiliitis . Dynamic MRI has crossing juxtaarticular fatty tissue. Structural changes 
been shown to be useful in the detection of both early (erosions, sclerosis, ankylosis) were scored in joint 
12,13 space, subchondral bone, and bone marrow. SI joint and spinal inflammation in AS .
In this study, our aim was to determine the 
Statistical analysisefficacy and safety of anti-TNF-á therapies for 
SPSS was used to analyze the data. Data were refractory AS and to assess the changes in the SI joints 
summarized as frequency and percentages. t-test was by MRI in a 24- week follow-up period before and 
used for comparison of numerical variables. The level after treatment.
of significance was accepted as p < 0.05.
MATERIALS and METHODS
RESULTS
Twenty-seven (18 men and 9 women) who met 
The mean age was 46,3±12,3 years (range 20-the modified New York criteria for AS and anti-TNF-
70) and mean disease duration was 12,1±3,4 years alpha naive patients were enrolled in this 24- week 
(range: 5-20). Ten patients were HLA-B27 positive. study. All patients gave written informed consent. 
Nine patients had peripheric arthritis and 8 patients Before study entry, all patients were evaluated for 
had enthesitis. Five patients had a prior history of latent tuberculosis by a tuberculin test and chest 
anterior uveitis (Table1). All 27 patients responded radiographs. Despite treatment with methotrexate 
well to treatment of anti TNF-alpha agents. At 24 (MTX) at least 10 mg/week, sulfasalazine (SSZ) 3 
weeks, there was an improvement in all of the g/day, corticosteroid 4 mg/day, nonsteroid 
following measures: BASDAI, BASFI, patient global antiinflammatory drugs (NSAIDs), at the time of 
enrollment, all patients had active disease. Disease 
modifying drugs, such as SSZ, MTX were not allowed 
during the study. Patients were allowed to continue 
NSAIDs and/or corticosteroids (<10 mg/day 
prednisolone), provided that the dosage and schedule 
regiment were stable at least 4 weeks prior to baseline 
and troughout the study. Eight patients received 
infliximab at a median dose of 4 mg/kg by intravenous 
infusion over 2 hours at every 4 week. Other 19 
patients were treated with 25 mg subcutaneous 
etanercept twice weekly. The total observational 
period was 24 weeks. The clinical variables included: 
Bath AS Disease Activity Ýndex (BASDAI), Bath AS 
Functional Index (BASFI), pain on a visual analog 
scale The laboratory variables for activity of disease 
included: C-reactive protein(CRP), erythrocyte assessment, physician global assessment, pain scores. sedimentation rate (ESR). All the above variables For BASDAI, there was a reduction from 6,3 at (clinical and laboratory ) were evaluated at week 0, 4, baseline to 3,5 at 24 weeks. ESR and CRP showed 8, 16, 24. Furhermore, a complete blood count and significant improvement at 6 weeks and were biochemical measurements were obtained at each maintained to the 24 week assessment point. The mean patient visit. baseline scores for inflammatory markers in the Activity of sacroiliitis was determined by Gd- peripheral blood were 53,4 mm/h for ESR(reference MRI scan before and after anti-TNF-alpha treatment. range 0-15), 3,5 mg/dl for CRP (reference range < 0,5 The following sequences were used: T1 weighted spin mg/dl). At week 24, there was an improvement in echo (SE), short tau inversion recovery (STIR), T2 inflammatory markers (median ESR were 16,2 mm/h, weighted fast SE with fat saturation and T1 weighted median CRP were 0,4 mg/dl respectively). Also SE with fat suppression after the intravenous peripheral arthritis, enthesitis and spinal symptoms administration of contrast medium (gadolinium improved. There was a improvement in Schober's diethylenetriaminepentate, 0.1 mmol/kg body index and chest expansion at 24 weeks, but there was weight). Inflammation was scored for each sacroiliac not statistically significant (Table2). Imaging studies joint in the joint space, subchondral bone, bone before and after 24 weeks of treatment with anti-TNF-marrow, ligaments, and joint capsule. Inflammation á was performed in 22 patients. Active inflammation was defined as a low signal intensity on T1, with depicted by MRI was seen in 20 patient (Table3). enhancement after gadolinium administration, and/or Among these patients, 12 had bilaterally sacroiliitis. high signal intensity on STIR, and/or T2 fast SE. Inflammation of the subchondral region and the bone Inflammation in ligaments was defined as areas of low marrow was the most frequently observed finding. signal intensity running through high signal intensity Only one patient had inflammation excluding the bone tissue on T1, which reflects interosseous ligaments marrow and subchondral bone. The pathological 
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Table 1. Demographic data of 27 patients with  ankylosing 
spondylitis.
Characteristic Patients
Age/years/mean 46.3±12.3
Disease duration/years 12.1±3.4
Sex/male 18(66.6%)
History of anterior üveitis 5(18.5%)
Peripheric arthritis 9(33.3%)
Enthesitis 8(29.6%)
HLA B-27 positivity 10(37%)
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findings were mostly scored as grade 2, representing reaction during the infusion. Infections was developed 
moderate involvement. Structural changes was seen in in 4 patients (one pneumonia, 3 urinary tract 
all 22 patients. Similarly to inflammation, about one infection). No patient developed ANA or anti-dsDNA 
half of the patients with structural changes showed antibodies. No clinical events occured to suggest a 
these changes bilaterally. Furthermore, after 24 weeks lupus-like illness in any patient.
of continuous treatment of 22 patients with AS with 
anti-TNF-á agents there was a slight but not DISCUSSION
significant decrease of the mean score for active 
inflammatory lesions in the SI joints. MRI showed Our study shows that treatment of patients with 
decreased inflammation of the SI joints in only 3 active AS with anti-TNF-á agents are not associated 
patients. Among these 3 patients, 2 were women and with a significant reduction of active inflammatory 
all of them has been treated with etanercept. All of changes of the sacroiliac joints as depicted by MRI. 
these 3 patients had positivity for HLA-B27 antigen. Active inflammatory findings as bone marrow 
Also no difference in chronic changes was found oedema and enhancement of the contrast agent was 
among the patients with AS after 24 weeks of persisted after 24 week follow period. Only 3 patients 
treatment with anti-TNF-á drugs. Despite clinically had regression of acute inflammatory findings 
and laboratory improvement there are no showed depicted by MRI. During the study, no progression 
regression of inflammatory findings of sacroiliac occurred of chronic changes of the SI joints as 
joints.  During follow-up of the treatment, 3 patients depicted by MRI. Results of studies of the influence of 
developed headache, one patient developed allergic anti-TNF-á treatments on spinal and sacroiliac joints 
Table 2.  Clinical and laboratory follow-up of patients with AS during anti-TNF-á  treatment. 
Follow-up BASDAI 
0-10cm 
Median 
BASFI 
0-10cm 
median 
ESR 
mm/h 
median 
CRP 
mg/dl 
median 
Pain 
0-10cm 
median 
Schober 
cm 
median 
Chest expansion 
cm 
median 
Baseline 6.3*±0.93 6.5*±0.97 53.4*±2.12 3.5*±0.74 7.2*±0.80 2.1±0.89 3.1±0.75 
8.week 3.0±1.03 2.5±0,58 17.4±1.97 0.6±0.93 3.1±1.01 3.5±0.74 4.0±1.29 
24.week 3.5*±0.74 2.8*±1.26 16.2*±1.93 0.4*±0.57 3.4*±0.77 4.1±1.27 5.2±1.33 
*t-test was performed, p<0.05 was accepted as significance 
Table 3. MRI findings of sacroiliac joints in 22 patients with AS before and after anti-TNF-á treatment.
MRI findings(R/L)
Active inflammation(R/L) Chronic changes(R/L)
Pts before treatment after treatment before treatment after  treatment
1 +/+ +/+ +/+ +/+   
2             -/+                       -/+                              +/+                        +/+
3              +/+                      +/+                               -/+                         -/+
4                 +/+                       -/-                               +/-                         +/-
5                  +/+                      +/+                              +/+                        +/+
6             -/+                       -/+                              +/+                        +/+
7             -/+                       -/+                               -/+                         -/+                                 
8               +/+                       -/-                               +/+                        +/+
9             +/+                      +/+                              +/+                        +/+
10          -/+                       -/+                              +/-                         +/- 
11           +/+                      +/+                              +/+                        +/+
12         +/+                       -/-                                -/+                         -/+                      
13           -/+                       -/+                               -/+                         -/+
14           +/+                      +/+                               +/+                       +/+
15         +/-                      +/-                                 -/+                        -/+            
16       -/+                       -/+                              +/+                       +/+
17       -/+                       -/+                               +/+                       +/+   
18          +/+                     +/+                               +/+                        +/+
19         +/+                     +/+                                -/+                         -/+
20           -/-                      -/-                                  -/+                      -/+
21         +/+                     +/+                                -/+                         -/+
22          -/-                       -/-                                +/-                          +/-
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